发明名称 |
RESPONSIVENESS TO ANGIOGENESIS INHIBITORS |
摘要 |
The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGF promoter gene and/or VEGFR2 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGF promoter gene and/or VEGFR2 gene. |
申请公布号 |
US2014294768(A1) |
申请公布日期 |
2014.10.02 |
申请号 |
US201414191040 |
申请日期 |
2014.02.26 |
申请人 |
Hoffmann-La Roche Inc. ;VIB vzw ;Life Sciences Research Partners vzw |
发明人 |
de Haas Sanne Lysbet;Delmar Paul;Lambrechts Diether;Scherer Stefan |
分类号 |
C07K16/22;C12Q1/68;A61K39/395 |
主分类号 |
C07K16/22 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of determining whether a patient is suitably treated by a therapy comprising an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizurnab, said method comprising:
(a) determining in a sample derived from a patient suffering from cancer the genotype at polymorphism rs699946 (SEQ ID NO. 1), and (b) identifying a patient as more or less suitably treated by a therapy comprising an angiogenesis inhibitor comprising bevacizumab or an antibody that binds essentially the same epitope on VEGF as bevacizumab based on said genotype, wherein the presence of each A allele at polymorphism rs699946 (SEQ ID NO. 1) indicates an increased likelihood that said patient is more suitably treated, or the presence of each G allele at polymorphism rs699946 (SEQ ID NO. 1) indicates an increased likelihood that said patient is less suitably treated. |
地址 |
Nutley NJ US |